Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.014
Buy
RSI(14)
58.708
Neutral
STOCH(KDJ)(9,3,3)
70.537
Neutral
ATR(14)
0.066
Low Volatility
CCI(14)
151.405
Buy
Williams %R
36.364
Buy
TRIX(12,20)
0.443
Sell
StochRSI(14)
55.163
Sell
Search
Biofrontera Inc
BFRIAdd to Watchlist
1.170USD
-0.060-4.88%
Close 07-31 16:00（ET）Quotes delayed by 15 min
13.89MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-4.88%
5 Days
+7.34%
1 Month
+23.74%
6 Months
+25.77%
Year to Date
+105.26%
1 Year
+8.33%
Key Figures
1.210Open
1.230High
433.14KVolume
LossP/E TTM
2.50P/E Dynamic
--Dividend TTM
3.65%Turnover Ratio
1.230Prev. Close
1.145Low
363.47KTurnover
LossP/E Static
2.29P/B
0.00%Div Yield TTM
-53.58%ROA
1.19052wk High
0.75Volume Ratio
-17.76MNet Profit
11.87MShares
-0.9689EPS TTM
0.85Beta
-339.04%ROE
0.53652wk Low
6.90%Amplitude
79.02%Gross Margin
13.89MMarket Cap
4.41Reward/Risk
4.93%Risk Rate
TradingKey Stock Score of Biofrontera Inc
Currency: USD Updated: 2026-07-31Key Insights
Biofrontera Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 75 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Biofrontera Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Biofrontera Inc Highlights
StrengthsRisks
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 22.41% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 41.70M.
Undervalued
The company’s latest PE is -1.21, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.75M shares, decreasing 9.14% quarter-over-quarter.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
6.000
Target Price
+412.82%
Upside Space
Biofrontera Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
2
analysts
Buy
Current Rating
6.000
Target Price
+412.82%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Biofrontera Inc
BFRI
2
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
1.146
Buy
MA10
1.112
Buy
MA20
1.114
Buy
MA50
1.007
Buy
MA100
0.991
Buy
MA200
0.934
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Biofrontera Inc Info
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
Ticker SymbolBFRI
CompanyBiofrontera Inc
CEOLuebbert (Hermann)
Websitehttps://www.biofrontera-us.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Biofrontera Inc (BFRI)?
The current price of Biofrontera Inc (BFRI) is 1.17.
What is the symbol of Biofrontera Inc?
The ticker symbol of Biofrontera Inc is BFRI.
What is the 52-week high of Biofrontera Inc?
The 52-week high of Biofrontera Inc is 1.19.
What is the 52-week low of Biofrontera Inc?
The 52-week low of Biofrontera Inc is 0.54.
What is the market capitalization of Biofrontera Inc?
The market capitalization of Biofrontera Inc is 13.89M.
Is Biofrontera Inc (BFRI) currently rated as Buy, Hold, or Sell?
According to analysts, Biofrontera Inc (BFRI) has an overall rating of Buy, with a price target of 6.00.
What is the Earnings Per Share (EPS TTM) of Biofrontera Inc (BFRI)?
The Earnings Per Share (EPS TTM) of Biofrontera Inc (BFRI) is -1.04.